NGNE - NASDAQ

Neurogene Inc.

NGNE·NASDAQ

$26.22

+0.31%

HealthcareBiotechnology

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$414.33M

EPS-4.2400

P/E Ratio-6.18

Earnings Date08/07/2026

ngne

Cash at Beginning of Period

Last Annual Value

136.93M

3-Year CAGR

25%

5-Year CAGR

-1%

10-Year CAGR

25%

Adjust for Inflation

Neurogene Inc. Competitors Analysis of Cash at Beginning of Period

NGNE · NASDAQ

Company	Cash at Beginning of Period	CAGR 3Y	CAGR 5Y	CAGR 10Y
Neurogene Inc. NASDAQ:NGNE	136.93M	18.6%	10.2%	13.2%
Ocugen, Inc. NASDAQ:OCGN	58.82M	-8.8%	19.4%	6.6%
Alumis Inc. Common Stock NASDAQ:ALMS	170.63M	85.0%	N/A	N/A
Rocket Pharmaceuticals, Inc. NASDAQ:RCKT	165.00M	5.2%	-11.2%	7.5%
4D Molecular Therapeutics, Inc. NASDAQ:FDMT	149.34M	41.8%	-11.6%	N/A
Inhibrx Biosciences, Inc. NASDAQ:INBX	152.60M	-17.7%	3.5%	31.9%
MBX Biosciences, Inc. Common Stock NASDAQ:MBX	49.35M	26.8%	N/A	N/A
Benitec Biopharma Inc. NASDAQ:BNTC	50.93M	132.0%	39.0%	12.1%
Lineage Cell Therapeutics, Inc. AMEX:LCTX	46.35M	57.2%	6.9%	0.9%
PureTech Health plc NASDAQ:PRTC	282.28M	23.5%	-6.9%	7.7%
Fulcrum Therapeutics, Inc. NASDAQ:FULC	59.41M	18.0%	0.4%	N/A

Neurogene Inc. Fair Value Envelope

NGNE · NASDAQ

Our analysis suggests that NGNE has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $26.22, this represents a potential HIDDEN relative to our calculated worth for Neurogene Inc..

HIDDEN

Intrinsic Value

Current Price: $26.22

Related Guides

Blog Categories

Continue your NGNE research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.